Trade data, page-41

Large volume on the sell side. I wonder if people are getting a bit impatient, or maybe are wary there may be more delays since two of the potential early access countries are being hit hard by covid at the moment (Japan and Canada).

I wouldn't be surprised if there were more delays, but I'd be very surprised if commercialisation got kicked down the road too far. While Canada and Japan are suffering, I have done some digging and it seems like IVF clinics are still running.

This, combined with the fact that both countries large surges appear to be tapering off, I'm not looking to sell. In fact, I'll be picking up another parcel soon in preparation for the commercialisation announcement.

If it's bad, sucks for that parcel, and I'll probably pick some more up and average down. I'm still very confident in the tech, and it's always a bit of a rocky road to commercialisation.

I'm looking out for things such as execs selling (I'd be very surprised) and negative reports from KOLs, as well as potential cap raises (we'll see how that's looking on the next report due soon).

The company is very undervalued at this stage if the boards projections for commercialisation are accurate.

Fingers crossed. DYOR